Immuron Ltd (IMC) - Net Assets
Based on the latest financial reports, Immuron Ltd (IMC) has net assets worth AU$8.07 Million AUD (≈ $5.71 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$10.13 Million ≈ $7.17 Million USD) and total liabilities (AU$2.06 Million ≈ $1.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IMC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$8.07 Million |
| % of Total Assets | 79.66% |
| Annual Growth Rate | 2.42% |
| 5-Year Change | -68.84% |
| 10-Year Change | 63.32% |
| Growth Volatility | 919.67 |
Immuron Ltd - Net Assets Trend (2000–2025)
This chart illustrates how Immuron Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Immuron Ltd for the complete picture of this company's asset base.
Annual Net Assets for Immuron Ltd (2000–2025)
The table below shows the annual net assets of Immuron Ltd from 2000 to 2025. For live valuation and market cap data, see Immuron Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$8.07 Million ≈ $5.71 Million |
-36.51% |
| 2024-06-30 | AU$12.71 Million ≈ $8.99 Million |
-35.21% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
-15.36% |
| 2022-06-30 | AU$23.18 Million ≈ $16.40 Million |
-10.49% |
| 2021-06-30 | AU$25.90 Million ≈ $18.32 Million |
+358.81% |
| 2020-06-30 | AU$5.64 Million ≈ $3.99 Million |
-23.22% |
| 2019-06-30 | AU$7.35 Million ≈ $5.20 Million |
-12.89% |
| 2018-06-30 | AU$8.44 Million ≈ $5.97 Million |
+28.36% |
| 2017-06-30 | AU$6.57 Million ≈ $4.65 Million |
+33.08% |
| 2016-06-30 | AU$4.94 Million ≈ $3.50 Million |
+2.70% |
| 2015-06-30 | AU$4.81 Million ≈ $3.40 Million |
-29.12% |
| 2014-06-30 | AU$6.79 Million ≈ $4.80 Million |
+4581.10% |
| 2013-06-30 | AU$144.99K ≈ $102.59K |
-92.93% |
| 2012-06-30 | AU$2.05 Million ≈ $1.45 Million |
+18.33% |
| 2011-06-30 | AU$1.73 Million ≈ $1.23 Million |
-48.49% |
| 2010-06-30 | AU$3.36 Million ≈ $2.38 Million |
+1919.26% |
| 2009-06-30 | AU$-184.87K ≈ $-130.81K |
-116.65% |
| 2008-06-30 | AU$1.11 Million ≈ $785.58K |
-44.05% |
| 2007-06-30 | AU$1.98 Million ≈ $1.40 Million |
-62.12% |
| 2006-06-30 | AU$5.24 Million ≈ $3.71 Million |
-24.77% |
| 2005-06-30 | AU$6.96 Million ≈ $4.93 Million |
+70.75% |
| 2004-06-30 | AU$4.08 Million ≈ $2.89 Million |
-19.15% |
| 2003-06-30 | AU$5.04 Million ≈ $3.57 Million |
-20.23% |
| 2002-06-30 | AU$6.32 Million ≈ $4.47 Million |
-15.41% |
| 2001-06-30 | AU$7.48 Million ≈ $5.29 Million |
+68.28% |
| 2000-06-30 | AU$4.44 Million ≈ $3.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Immuron Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8244320500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$88.87 Million | 1101.40% |
| Other Comprehensive Income | AU$1.64 Million | 20.32% |
| Total Equity | AU$8.07 Million | 100.00% |
Immuron Ltd Competitors by Market Cap
The table below lists competitors of Immuron Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Effnetplattformen Holding AB
ST:EFFH
|
$6.42 Million |
|
East Side Games Group Inc
TO:EAGR
|
$6.42 Million |
|
LEHNER INVESTMENTS AG
F:LEH
|
$6.43 Million |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
$6.44 Million |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
$6.40 Million |
|
Total Telcom Inc
V:TTZ
|
$6.40 Million |
|
Horizon Petroleum Ltd
V:HPL
|
$6.40 Million |
|
XP Power Ltd
LSE:XPP
|
$6.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immuron Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,709,444 to 8,069,055, a change of -4,640,389 (-36.5%).
- Net loss of 5,215,987 reduced equity.
- Share repurchases of 396,830 reduced equity.
- New share issuances of 396,827 increased equity.
- Other comprehensive income decreased equity by 1,534,293.
- Other factors increased equity by 2,109,894.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-5.22 Million | -64.64% |
| Share Repurchases | AU$396.83K | -4.92% |
| Share Issuances | AU$396.83K | +4.92% |
| Other Comprehensive Income | AU$-1.53 Million | -19.01% |
| Other Changes | AU$2.11 Million | +26.15% |
| Total Change | AU$- | -36.51% |
Book Value vs Market Value Analysis
This analysis compares Immuron Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.02x to 0.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | AU$1.85 | AU$0.03 | x |
| 2001-06-30 | AU$2.73 | AU$0.03 | x |
| 2002-06-30 | AU$2.15 | AU$0.03 | x |
| 2003-06-30 | AU$1.72 | AU$0.03 | x |
| 2004-06-30 | AU$1.38 | AU$0.03 | x |
| 2005-06-30 | AU$2.10 | AU$0.03 | x |
| 2006-06-30 | AU$1.55 | AU$0.03 | x |
| 2007-06-30 | AU$0.54 | AU$0.03 | x |
| 2008-06-30 | AU$0.29 | AU$0.03 | x |
| 2009-06-30 | AU$-0.04 | AU$0.03 | x |
| 2010-06-30 | AU$0.35 | AU$0.03 | x |
| 2011-06-30 | AU$0.15 | AU$0.03 | x |
| 2012-06-30 | AU$0.17 | AU$0.03 | x |
| 2013-06-30 | AU$0.01 | AU$0.03 | x |
| 2014-06-30 | AU$0.16 | AU$0.03 | x |
| 2015-06-30 | AU$0.06 | AU$0.03 | x |
| 2016-06-30 | AU$0.06 | AU$0.03 | x |
| 2017-06-30 | AU$0.06 | AU$0.03 | x |
| 2018-06-30 | AU$0.06 | AU$0.03 | x |
| 2019-06-30 | AU$0.05 | AU$0.03 | x |
| 2020-06-30 | AU$0.03 | AU$0.03 | x |
| 2021-06-30 | AU$0.12 | AU$0.03 | x |
| 2022-06-30 | AU$0.10 | AU$0.03 | x |
| 2023-06-30 | AU$0.09 | AU$0.03 | x |
| 2024-06-30 | AU$0.06 | AU$0.03 | x |
| 2025-06-30 | AU$0.03 | AU$0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immuron Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.58%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.26x
- Recent ROE (-64.64%) is above the historical average (-168.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -20.89% | -318.19% | 0.06x | 1.05x | AU$-2.30 Million |
| 2002 | -27.63% | -85.74% | 0.30x | 1.07x | AU$-2.31 Million |
| 2004 | -28.83% | -31.60% | 0.75x | 1.22x | AU$-1.57 Million |
| 2005 | -19.21% | -27.39% | 0.60x | 1.16x | AU$-2.03 Million |
| 2006 | -68.74% | -88.95% | 0.60x | 1.28x | AU$-4.08 Million |
| 2007 | -170.86% | -77.22% | 1.29x | 1.72x | AU$-3.47 Million |
| 2008 | -262.88% | -975.86% | 0.15x | 1.75x | AU$-2.97 Million |
| 2009 | 0.00% | -442.24% | 1.06x | 0.00x | AU$-2.30 Million |
| 2010 | -56.66% | -412.61% | 0.12x | 1.13x | AU$-2.24 Million |
| 2011 | -149.80% | -1212.98% | 0.08x | 1.54x | AU$-2.77 Million |
| 2012 | -112.08% | -511.68% | 0.12x | 1.77x | AU$-2.50 Million |
| 2013 | -2441.01% | -2363.27% | 0.06x | 17.43x | AU$-3.55 Million |
| 2014 | -36.76% | -254.33% | 0.13x | 1.12x | AU$-3.17 Million |
| 2015 | -55.96% | -268.54% | 0.17x | 1.25x | AU$-3.17 Million |
| 2016 | -143.08% | -706.12% | 0.11x | 1.79x | AU$-7.56 Million |
| 2017 | -103.49% | -487.33% | 0.17x | 1.26x | AU$-7.46 Million |
| 2018 | -35.68% | -163.38% | 0.20x | 1.10x | AU$-3.85 Million |
| 2019 | -63.34% | -195.04% | 0.28x | 1.16x | AU$-5.39 Million |
| 2020 | -51.86% | -116.23% | 0.41x | 1.10x | AU$-3.49 Million |
| 2021 | -32.38% | -5751.61% | 0.01x | 1.04x | AU$-10.97 Million |
| 2022 | -12.31% | -373.01% | 0.03x | 1.07x | AU$-5.17 Million |
| 2023 | -19.30% | -209.81% | 0.08x | 1.12x | AU$-5.75 Million |
| 2024 | -54.58% | -141.49% | 0.32x | 1.22x | AU$-8.21 Million |
| 2025 | -64.64% | -71.58% | 0.72x | 1.26x | AU$-6.02 Million |
Industry Comparison
This section compares Immuron Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immuron Ltd (IMC) | AU$8.07 Million | -20.89% | 0.26x | $6.41 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more